Metabolic syndrome in patients with psychotic disorders: Diagnostic issues, comorbidity and side effects of antipsychotics

Psychiatria Danubina

Volumn 22, Issue 1, 2010, Pages 69-74

  Kozumplik, Oliver ^a   Uzun, Suzana ^a   Jakovljević, Miro ^b,c  

^a Referentni centar za Alzheimerovu bolest i psihijatriju sta rijeivo t ne dobi   (Croatia)

^b KBC Zagreb   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Antipsychotics; Metabolic syndrome; Psychotic disorder; Side effects

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ANTHROPOMETRIC PARAMETERS; BIPOLAR DISORDER; BODY MASS; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DIET THERAPY; EXERCISE; HUMAN; INSULIN RESISTANCE; META ANALYSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PATIENT MONITORING; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WAIST CIRCUMFERENCE; WAIST TO HEIGHT RATIO; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; CROATIA; CROSS-SECTIONAL STUDY; DRUG EFFECT; EARLY DIAGNOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR;

ANTIPSYCHOTIC AGENTS; COMORBIDITY; CROATIA; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; HUMANS; METABOLIC SYNDROME X; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 77954365532     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 2004; 161:1-114.
2. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V, Taylor D, Vora J & Jones PB: Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007; 21:357-73. (Pubitemid 47077296)
3. Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S &Andreassen OA: Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008; 28:132-7. (Pubitemid 351417117)
4. Blonde L, Kan HJ, Gutterman EM, L'Italien GJ, Kim MS, Hanssens L & McQuade RD: Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. J Clin Psychiatry 2008; 69:741-8. (Pubitemid 351838683)
5. Blouin M, Tremblay A, Jalbert ME, Venables H, Bouchard RH, Roy MA & Alméras N: Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring) 2008; 16:1780-7.
6. Bouguerra R, Alberti H, Smida H, Salem LB, Rayana CB, El Atti J, Achour A, Gaigi S, Slama CB, Zouari B & Alberti KG: Waist circumference cut-off points for identification of abdominal obesity among the tunisian adult population. Diabetes Obes Metab 2007; 9(6):859-68. (Pubitemid 47555207)
7. Bushe C & Holt R: Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry 2004; 184:S67-71. (Pubitemid 38482546)
8. Correll CU, Frederickson AM, Kane JM & Manu P: Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89(1-3):91-100. (Pubitemid 44881290)
9. DE Hert M, Dekker JM, Wood D, Kahl KG, Holt RI & Möller HJ: Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009; 24:412-24.
10. DE Hert M, Schreurs V, Vancampfort D & VAN Winkel R: Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009; 8:15-22.
11. Jakovljevic M, Crncevic Z, Ljubicic D, Babic D, Topic R & Saric M: Mental disorders and metabolic syndrome: a fatamorgana or warning reality? Psychiatr Danub 2007; 19:76-86. (Pubitemid 47045674)
12. Fagiolini A & Goracci A: The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry 2009; 70 Suppl 3:22-9.
13. Kozumplik O & Uzun S: Recommendations from treatment guidelines for schizophrenia regarding monitoring of side effects of antipsychotics: brief review. Psychiatria Danubina 2009; 21:95-8.
14. Kozumplik O, Uzun S & Jakovljević M: Psychotic disorder and comorbidity: somatic illnes vs. side effect. Psychiatria Danubina 2009; 22:361-7.
15. Laursen TM, Munk-Olsen T, Agerbo E, Gasse C &Mortensen PB: Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 2009; 66:713-20.
16. Lee CM, Huxley RR, Wildman RP & Woodward M: Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol 2008; 61:646-53.
17. Lee JS, Kawakubo K, Mori K & Akabayashi A: BMI Specific Waist Circumference for Detecting Clusters of Cardiovascular Risk Factors in a Japanese Population. J Atheroscler Thromb 2010. [Epub ahead of print]
18. Leite ML & Nicolosi A: Dietary patterns and metabolic syndrome factors in a non-diabetic Italian population. Public Health Nutr 2009; 12:1494-503.
19. Lindenmayer JP, Khan A, Wance D, Maccabee N, Kaushik S & Kaushik S: Outcome evaluation of a structured educational wellness program in patients with severe mental illness. J Clin Psychiatry 2009; 70:1385-96.
20. Newcomer JW: Metabolic syndrome and mental illness. Am J Manag Care 2007; 13:S170-7.
21. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19:1-93.
22. Nicklas BJ, Wang X, You T, Lyles MF, Demons J, Easter L, Berry MJ, Lenchik L & Carr JJ: Effect of exercise intensity on abdominal fat loss during calorie restriction in overweight and obese postmenopausal women: a randomized, controlled trial. Am J Clin Nutr 2009; 89:1043-52.
23. Oud MJ & Meyboom-de Jong B: Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam Pract 2009; 10:32.
24. Park SH, Choi SJ, Lee KS & Park HY: Waist circumference and waist-to-height ratio as predictors of cardiovascular disease risk in Korean adults. Circ J 2009; 73(9):1643-50.
25. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO & Lieberman JA, CAFE Investigators: Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009; 111:9-16.
26. Reaven GM: Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988; 37:1595-607.
27. Ross R, Janssen I, Dawson J, Kungl AM, Kuk JL, Wong SL, Nguyen-Duy TB, Lee S, Kilpatrick K &Hudson R: Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. Obes Res 2004; 12:789-98. (Pubitemid 41127314)
28. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders: Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 2005; 39:1-30.
29. Ryan MC, Collins P & Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160:284-9. (Pubitemid 41110453)
30. Ryan J, Siriwardhana D & Vasikaran SD: An audit of oral glucose tolerance tests at a large teaching hospital: indications, outcomes and confounding factors. Ann Clin Biochem 2009; 46(Pt 5):390-3.
31. Saarni SE, Saarni SI, Fogelholm M, Heliövaara M, Perälä J, Suvisaari J &, Lönnqvist J: Body composition in psychotic disorders: a general population survey. Psychol Med 2009; 39:801-10.
32. Slentz CA, Houmard JA, Johnson JL, Bateman LA, Tanner CJ, McCartney JS, Duscha BD & Kraus WE: Inactivity, exercise training and detraining, and plasma lipoproteins. STRRIDE: a randomized, controlled study of exercise intensity and amount. J Appl Physiol 2007; 103:432-42. (Pubitemid 47204960)
33. VAN Winkel R, DE Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A & Peuskens J: Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry 2006; 67:1493-500.